Clinical Trial Update: Eltrombopag and Romiplostim Used Alternatively in Patients With Immune Thrombopenia (ITP): Efficacy and Safety.

View source ↗

Summary

This completed clinical trial compared alternating use of eltrombopag and romiplostim in immune thrombocytopenia and reported on efficacy and safety. The study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Nplate (romiplostim)
• Promacta (eltrombopag)

Snippet

Sponsor: Henri Mondor University Hospital | Conditions: Immune Thrombocytopenia, Thrombopoietin Receptor Agonist | Status: COMPLETED